Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)

View source ↗

Summary

An observational trial evaluating Rituximab in active rheumatoid arthritis patients with inadequate response to anti-TNF therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera/Rituxan (Rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: TERMINATED